INSYS Therapeutics Reports First Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher on modest rise in inflation
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 flat as higher bond yields counter tech optimism
Insys Therapeutics (INSY) Misses Q1 EPS by 1c
May 8, 2018 4:01 PM EDTInsys Therapeutics (NASDAQ: INSY) reported Q1 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $25.66 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More